Mehran Hariri

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Lundgren Mortensen, Anja Charlotte; Berglund, Hanna; Hariri, Mehran; Papalanis, Eleftherios et al.

Part of Scientific Reports, 2023

• DOI for Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
• Download full text (pdf) of Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines

Abramenkovs, Andris; Hariri, Mehran; Spiegelberg, Diana; Nilsson, Sten et al.

Part of Translational Oncology, 2022

• DOI for Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines
• Download full text (pdf) of Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines

p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

Lundsten, Sara; Berglund, Hanna; Jha, Preeti; Krona, Cecilia et al.

Part of Biomolecules, 2021

• DOI for p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids
• Download full text (pdf) of p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib

Mortensen, Anja; Mohajershojai, Tabassom; Hariri, Mehran; Pettersson, Marika et al.

Part of Frontiers in Oncology, 2020

• DOI for Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
• Download full text (pdf) of Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib

Ascorbate induces G2/M arrest and necrosis without  generation of direct DNA double-strand breaks

Hariri, Mehran; Papalanis, Eleftherios; Spiegelberg, Diana; Plotnikov, Evgenii et al.

Part of Heliyon, 2025

• DOI for Ascorbate induces G2/M arrest and necrosis without  generation of direct DNA double-strand breaks
• Download full text (pdf) of Ascorbate induces G2/M arrest and necrosis without  generation of direct DNA double-strand breaks

Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy

Uffenorde, Julia; Hariri, Mehran; Papalanis, Eleftherios; Staffas, Annika et al.

Part of Frontiers in Oncology, 2025

• DOI for Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy
• Download full text (pdf) of Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy

In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup

Sokol, Olga; Frederiksen, Anders Tobias; Sitarz, Mateusz; Sørensen, Brita Singers et al.

Part of Clinical and Translational Radiation Oncology, 2025

• DOI for In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup
• Download full text (pdf) of In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup

Breaking to Understand: DNA Repair in Response to Cancer Therapy

Hariri, Mehran

2025

• Download full text (pdf) of Breaking to Understand: DNA Repair in Response to Cancer Therapy

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Lundgren Mortensen, Anja Charlotte; Berglund, Hanna; Hariri, Mehran; Papalanis, Eleftherios et al.

Part of Scientific Reports, 2023

• DOI for Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
• Download full text (pdf) of Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Ascorbate induces G2/M arrest and necrosis without  generation of direct DNA double-strand breaks

Hariri, Mehran; Papalanis, Eleftherios; Spiegelberg, Diana; Plotnikov, Evgenii et al.

Part of Heliyon, 2025

• DOI for Ascorbate induces G2/M arrest and necrosis without  generation of direct DNA double-strand breaks
• Download full text (pdf) of Ascorbate induces G2/M arrest and necrosis without  generation of direct DNA double-strand breaks

Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy

Uffenorde, Julia; Hariri, Mehran; Papalanis, Eleftherios; Staffas, Annika et al.

Part of Frontiers in Oncology, 2025

• DOI for Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy
• Download full text (pdf) of Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy

In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup

Sokol, Olga; Frederiksen, Anders Tobias; Sitarz, Mateusz; Sørensen, Brita Singers et al.

Part of Clinical and Translational Radiation Oncology, 2025

• DOI for In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup
• Download full text (pdf) of In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Lundgren Mortensen, Anja Charlotte; Berglund, Hanna; Hariri, Mehran; Papalanis, Eleftherios et al.

Part of Scientific Reports, 2023

• DOI for Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
• Download full text (pdf) of Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines

Abramenkovs, Andris; Hariri, Mehran; Spiegelberg, Diana; Nilsson, Sten et al.

Part of Translational Oncology, 2022

• DOI for Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines
• Download full text (pdf) of Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines

p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

Lundsten, Sara; Berglund, Hanna; Jha, Preeti; Krona, Cecilia et al.

Part of Biomolecules, 2021

• DOI for p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids
• Download full text (pdf) of p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib

Mortensen, Anja; Mohajershojai, Tabassom; Hariri, Mehran; Pettersson, Marika et al.

Part of Frontiers in Oncology, 2020

• DOI for Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
• Download full text (pdf) of Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib

Breaking to Understand: DNA Repair in Response to Cancer Therapy

Hariri, Mehran

2025

• Download full text (pdf) of Breaking to Understand: DNA Repair in Response to Cancer Therapy